Loading organizations...
Edda provides comprehensive deal flow and portfolio management software solutions for venture capital and private equity investors, operating from an undisclosed headquarters location. The company offers an end-to-end software-as-a-service platform equipped with collaborative tools to manage investment pipelines, due diligence processes, fund performance tracking, and limited partner relationships. By automating routine data entry and generating detailed analytical reports, the centralized system facilitates faster investment decision-making for institutional asset managers worldwide. Currently, more than 140 distinct investment firms utilize the enterprise platform to actively manage over $135 billion in total assets under management. Edda serves a diverse global clientele of financial organizations across various industry focuses, including notable institutional customers such as FJ Labs, Bpifrance, and SG Innovate. The organization's exact founding year and specific founder names are not currently disclosed in available public records.
Edda has raised $6.0M across 1 funding round.
Edda has raised $6.0M in total across 1 funding round.
Edda has raised $6.0M in total across 1 funding round.
Edda's investors include Embedded Capital, FJ Labs, Pareto Holdings, Plug & Play Ventures, The Hit Forge, Valar Ventures, Guillaume Princen, Naveen Selvadurai, Steve Anavi.
EDDA Technology, Inc. is a medical technology company specializing in advanced imaging-guided precision surgery solutions for cancer treatment.[1][3][4] It develops the award-winning IQQA® platform, which provides fully quantitative, real-time 3D medical imaging analysis, simulation, and guidance to support the entire surgical workflow—from pre-surgical planning and intra-operative assistance to post-operative monitoring and follow-up.[3][4] The platform serves clinicians such as surgeons and oncologists, addressing challenges in cancer care by enabling early disease detection, precise treatment planning, and improved patient outcomes through patient-specific, disease-targeted approaches.[1][2][3] With strong growth momentum, EDDA recently completed a $150 million funding round led by SoftBank Vision Fund 2 and earned recognition on TIME's inaugural list of the World's Top Healthtech Companies in 2025.[2][6]
Headquartered in Princeton, New Jersey, with subsidiaries in Shanghai and Suzhou, China, EDDA reported $6.2 million in revenue and employs around 30 people as of recent data.[1][2] Its solutions enhance clinical efficiency and precision across open, minimally invasive, and robotic surgeries, positioning it as a key player in healthcare AI and imaging.[3][4]
Founded in 2003 as a privately held Delaware corporation, EDDA Technology emerged as an innovator in clinical computer solutions for healthcare imaging and analysis.[1][2] The company started with a focus on next-generation computer assistance for the patient care cycle, particularly enabling early detection and diagnosis of diseases.[1][2][5] Headquartered in Princeton, N.J., it expanded internationally with a subsidiary in Shanghai, China, and later added EDDA Technology (Shanghai) Ltd. and EDDA Technology Medical Solutions (Suzhou) Ltd.[1][2]
Key evolution came through developing the IQQA® platform, which shifted emphasis to precision 3D imaging for cancer surgery, incorporating real-time interactive tools for quantitative analysis and guidance.[3][4] Pivotal moments include participation in the global ACCLAIM prospective trial for microwave ablation in colorectal liver metastases, showcasing IQQA® BodyImaging's role in objective, reproducible outcomes, and the landmark $150 million financing in a recent round led by SoftBank Vision Fund 2, fueling growth in intelligent robotic surgery solutions.[2][4]
EDDA stands out in medical imaging through these key strengths:
EDDA rides the wave of AI-driven precision medicine and robotic surgery, where demand for real-time 3D imaging analytics is surging amid rising cancer incidences and minimally invasive procedure adoption.[3][4][6] Timing is ideal as healthcare shifts toward quantitative, data-backed decisions—EDDA's IQQA® addresses gaps in traditional 2D imaging by providing interactive 3D tools that boost surgical accuracy and reduce complications.[1][3] Market forces like aging populations, AI integration in medtech, and investments from giants like SoftBank favor EDDA, enabling scalable solutions amid a global push for efficient cancer therapies.[2][6]
The company influences the ecosystem by pioneering standards in imaging-guided interventions, as seen in clinical trials and TIME's 2025 Healthtech recognition, fostering adoption of Precision 3D approaches that empower clinicians worldwide.[4][6]
EDDA is poised for accelerated expansion with its $150M war chest, likely targeting deeper AI enhancements, robotic integrations, and global regulatory approvals to dominate imaging-guided oncology surgery.[2][6] Trends like generative AI in diagnostics, expanded robotic adoption, and value-based care will propel IQQA® into more procedures, potentially capturing shares in the booming $50B+ surgical robotics market. Its influence may evolve from niche innovator to ecosystem leader, partnering with device makers and hospitals to redefine precision cancer care—building on its core mission of turning advanced imaging into life-saving confidence.[3][4]
Edda has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in September 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2022 | $6M Seed | — | Embedded Capital, FJ Labs, Pareto Holdings, Plug & Play Ventures, The HIT Forge, Valar Ventures, Guillaume Princen, Naveen Selvadurai, Steve Anavi | Announced |
